Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 82

1.

MRI substudy participation in Alzheimer disease (AD) clinical trials: baseline comparability of a substudy sample to entire study population.

Raman R, Thomas RG, Weiner MW, Jack CR, Ernstrom K, Aisen PS, Tariot PN, Quinn JF.

Alzheimer Dis Assoc Disord. 2009 Oct-Dec;23(4):333-6. doi: 10.1097/WAD.0b013e3181aba588.

2.

Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial.

Farlow M, Potkin S, Koumaras B, Veach J, Mirski D.

Arch Neurol. 2003 Jun;60(6):843-8.

PMID:
12810489
4.

Volumetric MRI and cognitive measures in Alzheimer disease : comparison of markers of progression.

Ridha BH, Anderson VM, Barnes J, Boyes RG, Price SL, Rossor MN, Whitwell JL, Jenkins L, Black RS, Grundman M, Fox NC.

J Neurol. 2008 Apr;255(4):567-74. doi: 10.1007/s00415-008-0750-9. Epub 2008 Feb 18.

PMID:
18274807
5.

The cost-effectiveness of magnetic resonance imaging for investigation of the knee joint.

Bryan S, Weatherburn G, Bungay H, Hatrick C, Salas C, Parry D, Field S, Heatley F.

Health Technol Assess. 2001;5(27):1-95. Review.

6.

Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD.

Jack CR Jr, Shiung MM, Gunter JL, O'Brien PC, Weigand SD, Knopman DS, Boeve BF, Ivnik RJ, Smith GE, Cha RH, Tangalos EG, Petersen RC.

Neurology. 2004 Feb 24;62(4):591-600.

8.

Adding delayed recall to the Alzheimer Disease Assessment Scale is useful in studies of mild cognitive impairment but not Alzheimer disease.

Sano M, Raman R, Emond J, Thomas RG, Petersen R, Schneider LS, Aisen PS.

Alzheimer Dis Assoc Disord. 2011 Apr-Jun;25(2):122-7. doi: 10.1097/WAD.0b013e3181f883b7.

9.

Metal protein attenuating compounds for the treatment of Alzheimer's dementia.

Sampson EL, Jenagaratnam L, McShane R.

Cochrane Database Syst Rev. 2012 May 16;(5):CD005380. doi: 10.1002/14651858.CD005380.pub4. Review. Update in: Cochrane Database Syst Rev. 2014;(2):CD005380.

10.

Metal protein attenuating compounds for the treatment of Alzheimer's dementia.

Sampson EL, Jenagaratnam L, McShane R.

Cochrane Database Syst Rev. 2014 Feb 21;(2):CD005380. doi: 10.1002/14651858.CD005380.pub5. Review.

PMID:
24563468
11.
12.

The Alzheimer's Disease Assessment Scale: patterns and predictors of baseline cognitive performance in multicenter Alzheimer's disease trials.

Doraiswamy PM, Bieber F, Kaiser L, Krishnan KR, Reuning-Scherer J, Gulanski B.

Neurology. 1997 Jun;48(6):1511-7.

PMID:
9191757
13.

MRI as a biomarker of disease progression in a therapeutic trial of milameline for AD.

Jack CR Jr, Slomkowski M, Gracon S, Hoover TM, Felmlee JP, Stewart K, Xu Y, Shiung M, O'Brien PC, Cha R, Knopman D, Petersen RC.

Neurology. 2003 Jan 28;60(2):253-60.

14.

Galantamine for Alzheimer's disease.

Olin J, Schneider L.

Cochrane Database Syst Rev. 2001;(4):CD001747. Review. Update in: Cochrane Database Syst Rev. 2002;(3):CD001747.

PMID:
11687119
15.

Predictors of placebo group decline in the Alzheimer's disease Assessment Scale-cognitive subscale (ADAS-Cog) in 24 week clinical trials of Alzheimer's disease.

Irizarry MC, Webb DJ, Bains C, Barrett SJ, Lai RY, Laroche JP, Hosford D, Maher-Edwards G, Weil JG.

J Alzheimers Dis. 2008 Jul;14(3):301-11.

PMID:
18599956
16.

The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): design and baseline characteristics.

Jones RW, Kivipelto M, Feldman H, Sparks L, Doody R, Waters DD, Hey-Hadavi J, Breazna A, Schindler RJ, Ramos H; LEADe investigators..

Alzheimers Dement. 2008 Mar;4(2):145-53. doi: 10.1016/j.jalz.2008.02.001.

PMID:
18631958
17.

The dynamics of cortical and hippocampal atrophy in Alzheimer disease.

Sabuncu MR, Desikan RS, Sepulcre J, Yeo BT, Liu H, Schmansky NJ, Reuter M, Weiner MW, Buckner RL, Sperling RA, Fischl B; Alzheimer's Disease Neuroimaging Initiative..

Arch Neurol. 2011 Aug;68(8):1040-8. doi: 10.1001/archneurol.2011.167.

18.

Comparison of imaging biomarkers in the Alzheimer Disease Neuroimaging Initiative and the Mayo Clinic Study of Aging.

Whitwell JL, Wiste HJ, Weigand SD, Rocca WA, Knopman DS, Roberts RO, Boeve BF, Petersen RC, Jack CR Jr; Alzheimer Disease Neuroimaging Initiative..

Arch Neurol. 2012 May;69(5):614-22. doi: 10.1001/archneurol.2011.3029.

19.

Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial.

Freund-Levi Y, Eriksdotter-Jönhagen M, Cederholm T, Basun H, Faxén-Irving G, Garlind A, Vedin I, Vessby B, Wahlund LO, Palmblad J.

Arch Neurol. 2006 Oct;63(10):1402-8.

PMID:
17030655
20.

Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study.

Mulnard RA, Cotman CW, Kawas C, van Dyck CH, Sano M, Doody R, Koss E, Pfeiffer E, Jin S, Gamst A, Grundman M, Thomas R, Thal LJ.

JAMA. 2000 Feb 23;283(8):1007-15. Erratum in: JAMA 2000 Nov 22-29;284(20):2597.

PMID:
10697060

Supplemental Content

Support Center